There is a lack of comparative data and evident disparity between country-specific guidelines on the use of pembrolizumab monotherapy versus pembrolizumab combination chemotherapy in HNSCC patient cohort with PD-L1 CPS ≥1 in routine patient care [19,20]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.